TY  - JOUR
PY  - 2021//
TI  - A practical utility and benefit of pharmacogenetic-based antidepressant treatment strategy for major depressive disorder patients with difficult-to-treat
JO  - Clinical psychopharmacology and neuroscience
A1  - Lee, K.H.
A1  - Bahk, W.-m.
A1  - Lee, S.-j.
A1  - Serretti, A.
A1  - Pae, C.-u.
SP  - 160
EP  - 165
VL  - 19
IS  - 1
N2  - OBJECTIVE: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment- resistant major depressive disorder (TRD) patients in real practice. <br><br>METHODS: Nine patients were prescribed Neuropharmagen? for selection of antidepressants for individual patient and their clinical outcomes were followed. <br><br>RESULTS: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. <br><br>CONCLUSION: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients. © 2021 Korean College of Neuropsychopharmacology. All rights reserved.<p /> <p>Language: en</p>
LA  - en
SN  - 1738-1088
UR  - http://dx.doi.org/10.9758/CPN.2021.19.1.160
ID  - ref1
ER  -